^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rybrevant (amivantamab-vmjw) (EGFR inhibitor, c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Excerpt:
...- Participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous non-small cell lung cancer (NSCLC) with documented primary epidermal growth factor receptor (EGFR) Exon 20ins activating mutation...
Trial ID:
Source:
Title:
Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
Excerpt:
...Study treatment is followed by standard of care surgery, and (if clinically indicated) standard of care adjuvant therapy (chemotherapy, radiotherapy, EGFR tyrosine kinase inhibitor therapy) in patients with early stage or locally advanced non-small-cell lung cancer harboring oncogenic EGFR mutations who are eligible for curative resection....
Trial ID:
More C2 evidence
Source:
Title:
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Excerpt:
...Participants may be diagnosed with EGFR mutated or EGFR wild type NSCLC....
Trial ID:
Source:
Title:
A Clinical Study to Evaluate the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer Un estudio clínico para evaluar la seguridad y la eficacia de la terapia combinada de amivantamab y capmatinib en el cáncer de pulmón no microcítico metastásico irresecable
Excerpt:
...For Phase 2 – Expansion:- Cohort 1A: MET exon 14 skipping mutation (without prior therapy for metastatic disease)- Metastatic NSCLC previously characterized as MET exon 14 skipping mutation positive AND lacking EGFR and ALK mutation, by a local test using a CLIA certified laboratory or an accredited laboratory- Participant must not have received systemic anti-cancer therapy for metastatic NSCLC. ...
Trial ID:
Less C2 evidence
Source:
Title:
BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC)
Published date:
11/28/2023
Excerpt:
Sixty-one patients received amivantamab....In the classical mutation cohort of the 33 evaluable patients, twelve (36.4%) had clinical response and DCR was 48.5%. In the atypical mutation cohort, six of the seven patients (85.7%) had clinical response and DCR was 100%....Our real-world multi-center analysis demonstrated that amivantamab is a potentially effective treatment option for patients with EGFR mutations outside of Exon 20 insertion mutations.
DOI:
10.1016/j.jtho.2023.11.020
Source:
Title:
1343P - Amivantimab as a salvage strategy post TKI (osimertinib/mobocertinib) in EGFRm NSCLC
Published date:
10/16/2023
Excerpt:
...we present 13 patients who received amivantamab on top of their previous EGFR TKI for disease progression (Group A - common EGFRm+ & Group B - EGFR Exon20+)….The median progression-free survival was 4.7 months in both groups….Incorporating amivantamab to prior EGFR TKI treatment appears to be a feasible option, although osimertinib stands out as the most well-tolerated TKI with clinical efficacy.
Source:
Title:
Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC
Published date:
08/08/2023
Excerpt:
8 had common EGFR mutations (Group A) and 5 EGFR exon 20 (Group B). All group A patients had osimertinib as last line before amivantimab while Group B, 3 patients received mobocertinib, 1 afatinib and 1 poziotinib. Amivantamab was administered on top of previous line in all patients .The objective response rate (ORR) was 75% in group A and 100% in group B.